|
π
|
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
16 auth.
D. Weber,
Christine I. Chen,
R. Niesvizky,
Michael L. Wang,
A. Belch,
E. Stadtmauer,
D. Siegel,
I. Borrello,
S. Rajkumar,
A. Chanan-Khan,
...
S. Lonial,
Zhinuan Yu,
J. Patin,
Marta Olesnyckyj,
J. Zeldis,
R. Knight
|
10 |
2007 |
10
π
|
|
π
|
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
26 auth.
P. Richardson,
E. Blood,
C. Mitsiades,
S. Jagannath,
S. Zeldenrust,
M. Alsina,
R. Schlossman,
S. Rajkumar,
K. Desikan,
T. Hideshima,
Nikhil C. Munshi,
Kathleen Kelly-Colson,
D. Doss,
M. Mckenney,
S. Gorelik,
...
D. Warren,
A. Freeman,
Rebecca Rich,
A. Wu,
Marta Olesnyckyj,
K. Wride,
W. Dalton,
J. Zeldis,
R. Knight,
E. Weller,
K. Anderson
|
9 |
2006 |
9
π
|
|
π
|
Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma
12 auth.
M. Dimopoulos,
Christine I. Chen,
A. Spencer,
R. Niesvizky,
M. Attal,
E. Stadtmauer,
...
Maria Teresa Petrucci,
Zhinuan Yu,
Marta Olesnyckyj,
J. Zeldis,
R. Knight,
D. Weber
|
8 |
2009 |
8
π
|
|
π
|
Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma.
11 auth.
S. Rajkumar,
L. RosiΓ±ol,
M. Hussein,
J. Catalano,
W. JΔdrzejczak,
L. Lucy,
...
Marta Olesnyckyj,
Zhinuan Yu,
R. Knight,
J. Zeldis,
J. BladΓ©
|
8 |
2008 |
8
π
|
|
π
|
Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma.
16 auth.
P. Richardson,
S. Jagannath,
M. Hussein,
J. Berenson,
S. Singhal,
David E. Irwin,
S. Williams,
W. Bensinger,
A. Badros,
R. Vescio,
...
Laurie Kenvin,
Zhinuan Yu,
Marta Olesnyckyj,
J. Zeldis,
R. Knight,
K. Anderson
|
7 |
2009 |
7
π
|
|
π
|
The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function
11 auth.
M. Dimopoulos,
A. Alegre,
E. Stadtmauer,
H. Goldschmidt,
J. Zonder,
Carlos M. de Castro,
...
Z. Masliak,
D. Reece,
Marta Olesnyckyj,
Zhinuan Yu,
D. Weber
|
6 |
2010 |
6
π
|
|
π
|
Study of Lenalidomide Plus Dexamethasone Versus Dexamethasone Alone in Relapsed or Refractory Multiple Myeloma (MM): Results of a Phase 3 Study (MM-010).
10 auth.
M. Dimopoulos,
A. Spencer,
M. Attal,
M. Prince,
J. Harousseau,
A. DmoszyΕska,
...
Zhinuan Yu,
Marta Olesnyckyj,
J. Zeldis,
R. Knight
|
6 |
2005 |
6
π
|
|
π
|
Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma
12 auth.
J. Harousseau,
M. Dimopoulos,
Michael L. Wang,
A. Corso,
Christine I. Chen,
M. Attal,
...
A. Spencer,
Zhinuan Yu,
Marta Olesnyckyj,
J. Zeldis,
R. Knight,
D. Weber
|
6 |
2010 |
6
π
|
|
π
|
Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma
12 auth.
E. Stadtmauer,
D. Weber,
R. Niesvizky,
A. Belch,
M. Prince,
J. S. San Miguel,
...
T. Facon,
Marta Olesnyckyj,
Zhinuan Yu,
J. Zeldis,
R. Knight,
M. Dimopoulos
|
6 |
2009 |
6
π
|
|
π
|
Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): Results of a North American phase III study (MM-009).
10 auth.
D. Weber,
Christine I. Chen,
R. Niesvizky,
Michael L. Wang,
A. Belch,
E. Stadtmauer,
...
Zhinuan Yu,
Marta Olesnyckyj,
J. Zeldis,
R. Knight
|
6 |
2006 |
6
π
|
|
π
|
Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone.
11 auth.
J. San-Miguel,
M. Dimopoulos,
E. Stadtmauer,
S. Rajkumar,
D. Siegel,
M. Bravo,
...
Marta Olesnyckyj,
R. Knight,
J. Zeldis,
J. Harousseau,
D. Weber
|
6 |
2011 |
6
π
|
